Stockreport

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Conti [Read more]